glp-1 agonists australia Receptor Agonist Market Size & Outlook, 2033 Glucagon-like peptide-1 receptor agonists –

Through its dual insulinotropic and glucagonotropic effects on stabilizing glucose levels, GIP could provide a buffer against hyperglycemia when large amounts of glucose are consumed and mitigate reactive hypoglycemia, especially after meals with high fat content

Beyond obesity and type 2 diabetes, the therapeutic potential of GLP-1 RAs extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease, and substance abuse disorders

Bupropion may increase the risk of suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment

[DOI] [PMC free article] [PubMed] [Google Scholar] 99.Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al